Literature DB >> 18612622

Productively combining proteasome inhibition with the immunotherapy of cancer.

Thomas Sayers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18612622      PMCID： PMC2744476          DOI： 10.1007/s00109-008-0384-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  17 in total

Review 1.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 2.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

3.  Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Authors:  J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

4.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

5.  Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.

Authors:  Tahira Khan; Jimmy K Stauffer; Rebecca Williams; Julie A Hixon; Rosalba Salcedo; Erin Lincoln; Timothy C Back; Douglas Powell; Stephen Lockett; Alma C Arnold; Thomas J Sayers; Jon M Wigginton
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

6.  Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.

Authors:  Kai Sun; Lisbeth A Welniak; Angela Panoskaltsis-Mortari; Matthew J O'Shaughnessy; Haiyan Liu; Isabel Barao; William Riordan; Raquel Sitcheran; Christian Wysocki; Jonathan S Serody; Bruce R Blazar; Thomas J Sayers; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

7.  Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells.

Authors:  Alessio Nencioni; Anna Garuti; Karin Schwarzenberg; Gabriella Cirmena; Giovanna Dal Bello; Ilaria Rocco; Eleonora Barbieri; Peter Brossart; Franco Patrone; Alberto Ballestrero
Journal:  Eur J Immunol       Date:  2006-03       Impact factor: 5.532

8.  The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

Authors:  Thomas J Sayers; Alan D Brooks; Crystal Y Koh; Weihong Ma; Naoko Seki; Arati Raziuddin; Bruce R Blazar; Xia Zhang; Peter J Elliott; William J Murphy
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

9.  Comparison of HPV DNA vaccines employing intracellular targeting strategies.

Authors:  J W Kim; C-F Hung; J Juang; L He; T Woo Kim; D K Armstrong; S I Pai; P-J Chen; C-T Lin; D A Boyd; T-C Wu
Journal:  Gene Ther       Date:  2004-06       Impact factor: 5.250

10.  Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.

Authors:  Chih-Wen Tseng; Archana Monie; Chao-Yi Wu; Bruce Huang; Mei-Cheng Wang; Chien-Fu Hung; T-C Wu
Journal:  J Mol Med (Berl)       Date:  2008-06-10       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.